Renal Impairment Does Not Affect Pharmacokinetics, Safety or Tolerability of Zenagamtide.
A new dual-action weight-loss and diabetes drug works safely across all degrees of kidney disease, broadening treatment options for patients with both conditions.
This pharmacokinetics study demonstrates that zenagamtide—a novel dual GLP-1/amylin receptor co-agonist—maintains consistent PK parameters across the range of renal impairment severities, a critical property for its target T2D/obesity population where CKD is common. The renal-impairment-safe profile differentiates zenagamtide from other GLP-1 agents with more complex dosing in kidney disease and supports broad clinical development across the T2D+CKD spectrum.
What the study was
- Study design
- Phase 1/2 pharmacokinetics clinical study
- Population
- Participants with varying degrees of renal impairment and normal renal function receiving zenagamtide
- Category
- Drug Development
- Maturity
- Exploratory
- Journal
- Diabetes, obesity & metabolism
Why it surfaced
Novel dual GLP-1/amylin co-agonist with renal-impairment-safe PK supports development in the T2D+CKD population, a high-prevalence underserved group needing effective weight/glucose management without CKD dose restrictions.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.